Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices 65907 

tobacco control as part of the National 

Cancer Institute’s (NCI’s) Cancer 

Progress Report, and the Department of 

Health and Human Services’ Healthy 

People 2010 Goals. It is also relevant to 

past reports of NCI plans for the 

National Investment in Cancer Research 

and NCI’s long-term strategic plan for 

eliminating the suffering and death due 

to cancer. This survey is part of a 

continuing series of surveys that were 

sponsored by NCI and fielded 

periodically over the 1990’s by the 

Census Bureau as part of the American 

Stop Smoking Intervention Study for 

Cancer Prevention (ASSIST) project and 

made available for general public use. 

The Tobacco Use Supplements since 

2001–02 have been fielded and will be 

continuing over the next decade 

alternating between a standard or core 

tobacco use survey (such as this 2006–

2007 survey) and a special topic survey 

focusing on emerging adult tobacco 

control issues (such as the 2003 Tobacco 

Use Special Cessation Supplement). The 

survey will allow state specific 

estimates to be made. Data will be 

collected in May 2006, August 2006 and 

January 2007 from approximately 

285,000 respondents. The National 

Cancer Institute is co-sponsoring this 

survey with the Centers for Disease 

Control and Prevention. 

Frequency of Response: One-time 

study. 

Affected Public: Individuals or 

households. 

Type of Respondents: Persons 15 

years of age or older. The annual 

reporting burden is presented in exhibit 

1 below. There are no Capital Costs, 

Operating Costs and/or Maintenance 

Costs to report. 

EXHIBIT 1.—ESTIMATES OF RESPONDENT HOUR BURDEN

Number of respondents 

(number of annual respondents) 

Frequency of 

response 

Average burden hours per 

response 

Total hour 

burden (total 

annual hour 

burden) 

285,000 (95,000) ....................................................................................................................... 1 0.1169 33,317 (11,106 ) 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies should 

address one or more of the following 

points: (1) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(3) enhance the quality, utility and 

clarity of the information to be 

collected; and (4) minimize the burden 

of the collection of information on those 

who are to respond, including the use 

of appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Anne Hartman, 

M.S., M.A., Health Statistician, National 

Cancer Institute, Executive Plaza 

North—Suite 4005, 6130 Executive 

Blvd., MSC 7344, Bethesda, Maryland 

20892–7344, or call non-toll free (301) 

496–4970, or fax your request to (301) 

435–3710, or e-mail your request, 

including your address, to 

ah42t@nih.gov or 

Anne_Hartman@nih.gov. 

Comments Due Dates 

Comments regarding this information 

collection are best assured of having 

their full effect if received within 60 

days of the date of this publication. 

Dated: October 25, 2005. 

Rachelle Ragland-Greene, 

National Institutes of Health, NCI Project 

Clearance Liaison. 

[FR Doc. 05–21645 Filed 10–31–05; 8:45 am] 

BILLING CODE 4101–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 

Comment Request; Assessment of the 

Use of Special Funding for Research 

on Type 1 Diabetes Provided by the 

Balanced Budget Act of 1997, the FY 

2001 Consolidated Appropriations Act, 

and the Public Health Service Act 

Amendment for Diabetes 

Summary: Under the provisions of 

section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institute of Diabetes and Digestive and 

Kidney Diseases (NIDDK), the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. This proposed information 

collection was previously published in 

the Federal Register on March 10, 2005, 

page 11994 and allowed 60 days for 

public comment. No public comments 

were received. The purpose of this 

notice is to allow an additional 30 days 

for public comment. The National 

Institutes of Health may not conduct or 

sponsor, the respondent is not required 

to respond to, an information collection 

that has been extended, revised, or 

implemented on or after October 1, 

1995, unless it displays a currently valid 

OMB control number. 

Proposed Collection 

Title: Assessment of the Use of 

Special Funding for Research on Type 1 

Diabetes Provided by the Balanced 

Budget Act of 1997, and the FY 2001 

Consolidated Appropriations Act, and 

the Public Health Service Act 

Amendment for Diabetes. Type of 

Information Collection Requested: 

Revision, OMB control number: 0925–

0503; expiration date: 06/30/2005. Need 

and Use of Information Collection: This 

survey will be one source of input into 

a statutorily mandated assessment and 

report to the Congress on special 

funding for research on type 1 diabetes 

provided by the Balanced Budget Act of 

1997, (Pub. L. 105–33), the FY 2001 

Consolidated Appropriations Act, (Pub. 

L. 106–554), and the Public Health 

Service Act Amendment for Diabetes, 

(Pub. L. 107–360). Collectively, these 

Acts provided $1.14 billion in special 

funds to the Department of Health and 

Human Services (HHS) for research 

aimed at understanding, treating, and 

preventing type 1 diabetes and its 

complications. The Secretary of HHS 

subsequently designated to the NIDDK 

the lead responsibility in the 

Department for developing a process for 

allocation of these funds. The primary 

objective of this study is to gain 

information, via a brief questionnaire, 

from NIH research grantees who were 

the primary recipients of these special 

funds, concerning their views on the 

impact of the type 1 diabetes research 

65908 Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices 

fundings with respect to: (1) Advancing 

scientific accomplishments involving 

innovative, clinically relevant, and 

multidisciplinary research on type 1 

diabetes; (2) developing resources or 

reagents useful for type 1 diabetes 

research; and (3) increasing the number 

and quality of type 1 diabetes 

investigators. The responses will 

provide valuable information 

concerning how the funds have 

facilitated research as intended by these 

Acts of the Congress. The results will 

also help determine how research 

progress from these special 

congressional initiatives fits within the 

continuum of diabetes research, and 

how these funds have contributed to the 

field of type 1 diabetes research and 

NIH efforts to combat this challenging 

health problem. Information from this 

study will aid in evaluation of the 

process by which the research goals for 

use of the special type 1 diabetes funds 

have been developed and are being 

pursued. Responses already collected 

from this survey were analyzed as part 

of an interim program assessment that 

was published by the NIDDK in April, 

2003 http://www.niddk.nih.gov/federal/ 

planning/type 1_specialfund/. This 

revised survey will contribute to a 

statutorily mandated report, due to the 

Congress on January 1, 2007, evaluating 

the process and efforts under this 

program and assessing research 

initiatives funded by these Act of 

Congress. Frequency of Response: The 

survey will require a one time response; 

though, respondents may be contacted 

again in the event of future 

congressionally mandated reports on the 

use of the special type 1 diabetes 

research funds. Affected Public: 

Research scientists who received the 

special funds about which the Congress 

has mandated in law the requirements 

for an evaluation report. Type of 

Respondents: Laboratory and clinical 

investigators who have received support 

from the special type 1 diabetes funds 

provided under the laws previously 

cited. The annual reporting burden is as 

follows: Estimated number of 

respondents: 500; Estimated Number of 

Responses per Respondent: 1; Average 

Burden Hours per Response: 1; and 

Estimated Total Burden Hours 

Requested: 500. The annualized total 

cost to respondents is estimated at: 

$25,000. It is expected that the 

respondents will be contacted and will 

return their responses via electronic 

mail. These measures will reduce the 

burden on the respondents and the 

overall costs of administering the study. 

Respondents will be asked to answer no 

more than sixteen questions, one-third 

of which will be answered with ‘‘yes’’

or ‘‘no’’ or a one-word response. There 

are no Capital Costs, Operating Costs or 

Maintenance Costs to report. 

Request For Comments 

Written comments and/or suggestions 

from the public and affected agencies 

are invited on one or more of the 

following points: (1) Whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) The accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions sued; (3) 

Ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Ways to minimize the 

burden of the collection of information 

on those who are to respond, including 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

Direct Comments to OMB 

Written comments and/or suggestions 

regarding the item(s) contained in this 

notice, especially regarding the 

estimated public burden and associated 

response time, should be directed to the: 

Office of Management and Budget, 

Office of Regulatory Affairs, New 

Executive Office Building, Room 10235, 

Washington, DC 20503, Attention: Desk 

Officer for NIH. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and instruments, contact: Dr. 

Shefa Gordon, Presidential Management 

Fellow, Office of Scientific Program and 

Policy analysis, NIDDK, NIH, Building 

31, Room 9A31, 9000 Rockville Pike, 

Bethesda, MD 20892, or call non-tollfree number (301) 496–6623 or e-mail 

your request, including your address, to: 

gordonshefa@mail.nih.gov. 

Comments Due Date 

Comments regarding this information 

collection are best assured of having 

their full effect if received within 30 

days of the date of this publication. 

Dated: October 19, 2005. 

Barbara Merchant, 

Executive Officer, NIDDK. 

[FR Doc. 05–21649 Filed 10–31–05; 8:45 am] 

BILLING CODE 4140–01—M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of Biotechnology Activities, 

Office of Science Policy, Office of the 

Director; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the second meeting of 

the National Science Advisory Board for 

Biosecurity (NSABB). 

Under authority 42 U.S.C. 217a, 

Section 222 of the Public Health Service 

Act, as amended, the Department of 

Health and Human Services established 

NSABB to provide advice, guidance and 

leadership regarding federal oversight of 

dual-use research, defined as biological 

research with legitimate scientific 

purposes that could be misused to pose 

a biological threat to public health and/ 

or national security. 

The meeting will be open to the 

public, however, pre-registration is 

strongly recommended due to space 

limitations. Persons planning to attend 

should register online at http:// 

www.biosecurityboard.gov/meetings.asp 

or by calling The Hill Group (Contact: 

A.J. Bownas) at 301–897–2789, ext. 100. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

indicate these requirements upon 

registration. 

Name of Committee: National Science 

Advisory Board for Biosecurity. 

Date: November 21, 2005. 

Open: 9 a.m. to 6 p.m. 

Agenda: Presentations and discussions 

regarding: (1) Criteria for defining dual-use 

research in the life sciences; (2) the role of 

a code of conduct for the life sciences; (3) 

communication of dual use research; (4) 

international perspectives on dual use 

research; (5) public comments; and (6) and 

other business of the Board. 

Place: The National Institutes of Health, 

Building 31, 6C—Room 10, Bethesda, 

Maryland. 

Contact Person: Allison Chamberlain, 

NSABB Program Assistant, 6705 Rockledge 

Drive, Bethesda, Maryland 20892, (301) 402–

3090. 

This meeting will also be webcast. The 

draft meeting agenda and other information 

about NSABB, including information about 

access to the webcast and pre-registration, 

will be available at http:// 

www.biosecurityboard.gov/meetings.asp. 

Any member of the public interested in 

presenting oral comments at the meeting may 

notify the Contact Person listed on this notice 

at least 10 days in advance of the meeting. 

Interested individuals and representatives of 

an organization may submit a letter of intent, 

a brief description of the organization